Sanofi-Aventis's oral MS candidate shows promise in combination
This article was originally published in Scrip
Sanofi-Aventis's oral multiple sclerosis drug candidate teriflunomide produced a significant improvement in disease activity after one year as measured by the number of gadolinium enhancing T1 lesions compared with placebo, in patients with relapsing disease also taking interferon-beta, in a Phase II study.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.